A groundbreaking series A funding round has positioned London-based Verdiva Bio at the forefront of the obesity treatment sector, securing an impressive $411 million investment. This remarkable achievement stands as Europe’s largest biopharma series A fundraising to date.
The substantial funding round was orchestrated by Dutch investor Forbion and American private equity powerhouse General Atlantic, coinciding strategically with the upcoming JP Morgan healthcare conference. Verdiva Bio’s recent acquisition of global development and commercialisation rights to weightloss assets from Sciwind Biosciences, excluding China and South Korea, has strengthened its market position.
Under the leadership of industry veteran Khurem Farooq, who previously steered Aiolos Bio to a successful $1.4 billion acquisition by GSK, Verdiva Bio is poised to challenge established players in the burgeoning weightloss drug market. The sector, currently dominated by Danish firm Novo Nordisk and American pharmaceutical giant Eli Lilly, is projected to reach a staggering $150 billion valuation by the early 2030s.
The company’s innovative portfolio includes both oral and injectable treatments, with a particular focus on their phase 2-ready, once-weekly oral glucagon-like peptide-1 receptor agonist. This breakthrough treatment mechanism mirrors the successful approach of Wegovy while potentially offering improved accessibility and affordability.
Mohamed Eid, formerly of Novo Nordisk and now Verdiva’s chief medical officer, emphasises the company’s commitment to developing sustainable weightloss solutions. The firm’s 35-strong team, split between London and San Francisco, is backed by an impressive roster of investors including Lilly Asia Ventures, RA Capital Management, OrbiMed, Logos Capital, and LYFE Capital.
This landmark investment signals growing confidence in the obesity treatment market and positions Verdiva Bio as a serious contender in the race to develop next-generation weightloss therapies. The company’s focus on oral treatments and combination programmes could potentially reshape patient access to effective obesity treatments worldwide.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.